Comparison of the Recombinant Escherichia coli-Produced Protease Domain of Tissue-Type Plasminogen Activator with Alteplase, Reteplase and Streptokinase in a Canine Model of Coronary Artery Thrombolysis

Summary

Recent in vitro studies have shown that although recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator (t-PA) has no appreciable fibrin binding and less plasmin-forming activity compared to the wild-type, it is nevertheless an effective fibrinolytic agent in a dynamic in vitro plasma clot lysis system. The purpose of the present study was to evaluate the pharmacological profile of the protease in a canine model of coronary artery thrombosis. The effects of a single i.v. bolus injection of 1 mg/kg protease were compared with those of alteplase, reteplase and streptokinase at clinically relevant doses and dosing regimens in eight dogs per group. The protease rapidly restored coronary blood flow at 12 ± 1 min in all treated dogs with a significantly higher maximal coronary blood flow than in the reference groups, but was associated with short cycles of reocclusion in 4/8 animals. Overall, the coronary blood flow quality of the protease was not significantly different from that of the reference thrombo-lytics. Although fibrinogen was nearly completely degraded during protease treatment, the bleeding time was not significantly more prolonged than in reference groups. In conclusion, the protease domain is a rapidly acting, effective, bolus-injectable thrombolytic agent associated with a systemic lytic state and does not appear to cause significantly more bleeding than the reference thrombolytic agents.

• References

• 1 Verheijen JH, Caspers MPM, Chang GTG, de Munk GAW, Pouwels PH, Enger-Valk BE. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-3530
• 2 Dodd I, Fears R, Robinson JH. Isolation and preliminary characterization of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemost 1986; 55: 94-97
• 3 Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-3102
• 4 Kohnert U, Hellerbrand K, Martin U, Stern A, Popp F, Fischer S. The recombinant Escherichia coli-dtmed protease-domain of tissue-type plasminogen activator is a potent and fibrin specific fibrinolytic agent. Fibrinolysis 1996; 10: 93-102
• 5 Martin U, Kohnert U, Hellerbrand K, Stem A, Popp F, Doerge L, Stegmeier K, Muller-Beckmann B, Fischer S. Effective thrombolysis by a recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator in the rabbit model of jugular vein thrombosis. Fibrinolysis 1996; 10: 87-92
• 6 Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992; 19: 433-440
• 7 Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980; 17: 841-853
• 8 Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJD, Stem A, Opitz U, Martin U, Lill H, Prinz H, Lechner M, Kresse GB, Buckel P, Fischer S. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 93-100
• 9 Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide - comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-815
• 10 Larrieu MJ, Weilland C. Utilisation de la “cephaline” dans les tests de coagulation. Rev Hematol 1957; 12: 199-210
• 11 Martin U, von Mollendorff E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-574
• 12 Conover WJ, Iman RL. Rank transformation as a bridge between parametric and nonparametric statistics. Americ Statistician 1981; 35: 124-133
• 13 Zerbe GO, Walker SH. A randomization test for comparison of groups of growth curves with different polynomial design matrices. Biometrics 1977; 33: 653-657
• 14 Bode C, Smalling RW, Kalbfleisch J, Berg G, Odenheimer DJ, Boehm E, Weaver WD. Randomized comparison of double bolus reteplase (rPA) and front-loaded alteplase in patients with acute myocardial infarction (RAPID II). Eur Heart J 1995; 11 (abstr. suppl.): abstr. 131
• 15 The INJECT Study Group. A randomized, double blind comparison of reteplase, 10+10 MU double bolus administration, with streptokinase in patients with acute myocardial infarction (INJECT). Lancet 1995; 346: 329-336
• 16 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction New Engl J Med 1993; 329: 673-82
• 17 Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 1993; 21: 502-510
• 18 Kohnert U, Horsch B, Fischer S. A variant of tissue type plasminogen activator (t-PA) comprised of the kringle 2 and the protease domain shows a significant difference in the in vitro rate of plasmin formation as compared to the recombinant human t-PA from transformed Chinese hamster ovary cells. Fibrinolysis 1993; 7: 365-372
• 19 Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-1544
• 20 Blinc A, Kennedy SD, Bryant RG, Marder VJ, Francis CW. Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994; 71: 230-235
• 21 Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-2643